All the Active Ingredient Drugs
Decarboxylase Inhibitor. foslevodopa 240 mg/ml, foscarbidopa 12 mg/ml. foscarbidopa 12 mg, foslevodopa 240 mg / ml
Vial, sol. for SC inf. 7 X 10 ml
See Prescr. info. Continuous 3 d. SC. infusion. Max recomm. dly. dose of foslevodopa is 6000 mg (or 25 ml of Produodopa /d equiv. to approx. 4260 mg levodopa p/d.)
Tmt. of adv. levodopa-responsive Parkinson’s dis. with sev. motor fluctuat. and hyperkinesia or dyskinesia when available combin. of Parkinson medic. prod. have not given satisfact. results.
C/I: hypersens/narrow-angle glaucoma / severe HF /acute stroke /severe cardiac arrhythmia /non-selective MAO inhibit. and selective MAO type A inhibit. are contraindic. for use with this prod. These inhibit. must be discont. at least two weeks prior to init. this ther. May be admin. concomit. with the manufacturer’s recomm. dose of a MAO inhib. with selectiv. for MAO type B (e.g., selegiline HCl) / condit. in which medicat. with adrenergic activ. are contraindic., e.g., pheochromocytoma, hyperthyroidism and Cushing’s syndr.
Because levodopa may activate malign. melanoma, not be used in pts. with suspic. undiagn. skin lesions or a hist. of melanoma
